Cargando…

Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis

BACKGROUND: Cholinesterase inhibitors, such as galantamine, donepezil and rivastigmine are approved for symptomatic treatment of Alzheimer's Disease (AD) in Canada. In making choices amongst these drugs, one should consider their clinical merits and their economic implications. METHODS: Each dr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caro, Jaime, Getsios, Denis, Migliaccio-Walle, Kristen, Ishak, Jack, El-Hadi, Wissam
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2003
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC317304/ https://www.ncbi.nlm.nih.gov/pubmed/14675494 http://dx.doi.org/10.1186/1471-2318-3-6

Ejemplares similares

To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers?
por: Caro, Jaime, et al.
Publicado: (2002)

The time course of subsequent hospitalizations and associated costs in survivors of an ischemic stroke in Canada
por: Caro, J Jaime, et al.
Publicado: (2006)

The morbidity and mortality following a diagnosis of peripheral arterial disease: Long-term follow-up of a large database
por: Caro, Jaime, et al.
Publicado: (2005)

Invasive meningococcal disease epidemiology and control measures: a framework for evaluation
por: Caro, J Jaime, et al.
Publicado: (2007)

Cholinesterase inhibitors as Alzheimer's therapeutics
por: Sharma, Kamlesh
Publicado: (2019)

Adult Vaccination Strategies for the Control of Pertussis in the United States: An Economic Evaluation Including the Dynamic Population Effects
por: Coudeville, Laurent, et al.
Publicado: (2009)

Evaluation of the consequences associated with diffuse vascular disease history in patients diagnosed with peripheral arterial disease: estimates from Saskatchewan health data
por: Migliaccio-Walle, Kristen, et al.
Publicado: (2010)

The Impact of Menstrual Cycle Phase on Economic Choice and Rationality
por: Lazzaro, Stephanie C., et al.
Publicado: (2016)

Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease
por: Hu, Ziheng, et al.
Publicado: (2018)

Response to cholinesterase inhibitors affects lifespan in Alzheimer’s disease
por: Wattmo, Carina, et al.
Publicado: (2014)

Rational or rationalized choices in fluid resuscitation?
por: Han, Jenny, et al.
Publicado: (2010)

Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease
por: Parsons, Chris G., et al.
Publicado: (2013)

CHRNA7 Polymorphisms and Response to Cholinesterase Inhibitors in Alzheimer's Disease
por: Weng, Pei-Hsuan, et al.
Publicado: (2013)

Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer’s Disease
por: Hussein, Weiam, et al.
Publicado: (2018)

Odor identification impairment and cholinesterase inhibitor treatment in Alzheimer's disease
por: Motter, Jeffrey N., et al.
Publicado: (2021)

Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada
por: Ali, Thibault B., et al.
Publicado: (2015)

Rationality and the illusion of choice
por: Evans, Jonathan St. B. T.
Publicado: (2014)

Exploring Mannosylpurines as Copper Chelators and Cholinesterase Inhibitors with Potential for Alzheimer’s Disease
por: Schino, Ignazio, et al.
Publicado: (2022)

Economic Rationality in Choosing between Short-Term Bad-Health Choices and Longer-Term Good-Health Choices
por: Campbell, David
Publicado: (2013)

Economics and social choice /
por: Nickson, Jack W.
Publicado: (1971)

A simple model suggesting economically rational sample-size choice drives irreproducibility
por: Braganza, Oliver
Publicado: (2020)

A critical review of cholinesterase inhibitors as a treatment modality in Alzheimer's disease
por: S. Schneider, Lon
Publicado: (2000)

Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease
por: Rountree, Susan D, et al.
Publicado: (2009)

Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review
por: Farrimond, Lucy E, et al.
Publicado: (2012)

Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer’s disease cohort
por: Wattmo, Carina, et al.
Publicado: (2012)

Screening and analysis of acetyl-cholinesterase (AChE) inhibitors in the context of Alzheimer's disease
por: Khan, Mohd. Babu, et al.
Publicado: (2018)

Effect of QT Prolongation in Patients Taking Cholinesterase Inhibitors (Donepezil) for Alzheimer’s Disease
por: Kuwahata, So, et al.
Publicado: (2021)

Development of substituted benzylidene derivatives as novel dual cholinesterase inhibitors for Alzheimer's treatment
por: Gupta, Shraddha Manish, et al.
Publicado: (2023)

Rationally inattentive intertemporal choice
por: Gershman, Samuel J., et al.
Publicado: (2020)

Alzheimer's disease and Type 2 diabetes mellitus: the cholinesterase connection?
por: Allam, Appa Rao, et al.
Publicado: (2006)

Accounting for the relationship between per diem cost and LOS when estimating hospitalization costs
por: Ishak, K Jack, et al.
Publicado: (2012)

Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation
por: Hartz, Susanne, et al.
Publicado: (2012)

Cholinesterase inhibitors from botanicals
por: Ahmed, Faiyaz, et al.
Publicado: (2013)

Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: A meta-analysis
por: Campbell, Noll, et al.
Publicado: (2008)

Synthesis of Brominated 2-Phenitidine Derivatives as Valuable Inhibitors of Cholinesterases for the Treatment of Alzheimer’s Disease
por: Abbasi, Muhammad Athar, et al.
Publicado: (2014)

Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story
por: Lam, Benjamin, et al.
Publicado: (2009)

Reassessment of the dementia diagnosis of Alzheimer's disease in patients enrolled on the cholinesterase inhibitors dispensation program
por: Piovesana, Magda Cristina Flaitt Sanches, et al.
Publicado: (2012)

Serum Concentrations of Cholinesterase Inhibitors in Patients With Alzheimer’s Dementia Are Frequently Below the Recommended Levels
por: Ortner, Marion, et al.
Publicado: (2020)

First-in-Class Isonipecotamide-Based Thrombin and Cholinesterase Dual Inhibitors with Potential for Alzheimer Disease
por: Purgatorio, Rosa, et al.
Publicado: (2021)

Neuroprotective Effects of Cholinesterase Inhibitors: Current Scenario in Therapies for Alzheimer’s Disease and Future Perspectives
por: Moreira, Natália Chermont dos Santos, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g4p3i49qhbm5krdjj4pdcn9v2f